エグザクトサイエンス株式会社（本社：東京都千代田区、代表取締役：ジェフリー・ヘイゼマー）は、2021年12月1日に開催されました中央社会保険医療協議会にて、「オンコタイプDX乳がん再発スコア®プログラム」（一般的名称：腫瘍悪性度判定支援 ...

New York, July 25, 2023 (GLOBE NEWSWIRE) -- The global breast recurrence score test market stood at US$ 216.8 million in 2022 and is forecasted to expand at a CAGR of 9.2% from 2023 to 2033. Genomic ...

A retrospective study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker of adjuvant chemotherapy benefit in women with estrogen receptor (ER)-positive/human epidermal ...

Overall, 597 of 630 patients were analyzable—247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for ...